Celldex Therapeutics (NASDAQ:CLDX) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

Key Points

• Cantor Fitzgerald raised Celldex Therapeutics’ price target to $72 from $61 and maintained an “overweight” rating, implying 113.64% upside from the stock’s $33.70 price. Analysts overall give the stock a “Moderate Buy” consensus rating with an average target of $57.33.
• CLDX shares fell 11.1% to $33.70 on Tuesday, with trading volume significantly above average. The company reported a quarterly loss of $0.94 per share, beating the consensus estimate of a $1.06 loss, but revenue of $0.02 million trailed expectations.
• Several institutional investors increased their holdings in Celldex, including Bank of America, which raised its stake by 70.8%, and Quantinno Capital Management, which increased its position by 178.7%.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) had its price objective upped by analysts at Cantor Fitzgerald from $61.00 to $72.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has an "overweight" rating on the biopharmaceutical company's stock. Cantor Fitzgerald's target price suggests a potential upside of 113.64% from the company's current price.

A number of other analysts have also recently issued reports on the company. HC Wainwright reissued a "buy" rating and set a $42.00 target price on shares of Celldex Therapeutics in a research note on Monday, June 15th. Wells Fargo & Company lifted their price target on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. UBS Group upped their price target on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a "buy" rating in a report on Wednesday, June 10th. Morgan Stanley increased their price objective on shares of Celldex Therapeutics from $46.00 to $50.00 and gave the stock an "overweight" rating in a research report on Thursday, September 10th. Finally, Wall Street Zen upgraded shares of Celldex Therapeutics from a "strong sell" rating to a "sell" rating in a report on Sunday, July 12th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $57.33.

Celldex Therapeutics Trading Down 11.1%

Shares of CLDX stock traded down $4.19 on Tuesday, hitting $33.70. The stock had a trading volume of 7,458,498 shares, compared to its average volume of 975,002. Celldex Therapeutics has a twelve month low of $22.10 and a twelve month high of $45.14. The firm has a market cap of $2.65 billion, a P/E ratio of -7.75 and a beta of 0.84. The company has a fifty day moving average price of $39.12 and a two-hundred day moving average price of $34.81.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.12. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.73 million. On average, analysts expect that Celldex Therapeutics will post -4.17 earnings per share for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

A number of large investors have recently modified their holdings of CLDX. Quantinno Capital Management LP lifted its holdings in shares of Celldex Therapeutics by 178.7% in the 1st quarter. Quantinno Capital Management LP now owns 65,744 shares of the biopharmaceutical company's stock worth $2,085,000 after purchasing an additional 42,158 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Celldex Therapeutics by 70.8% in the first quarter. Bank of America Corp DE now owns 708,647 shares of the biopharmaceutical company's stock worth $22,478,000 after purchasing an additional 293,759 shares during the last quarter. First Trust Advisors LP lifted its holdings in shares of Celldex Therapeutics by 78.7% in the first quarter. First Trust Advisors LP now owns 68,470 shares of the biopharmaceutical company's stock valued at $2,172,000 after purchasing an additional 30,157 shares in the last quarter. Sei Investments Co. bought a new position in shares of Celldex Therapeutics in the first quarter valued at approximately $1,210,000. Finally, Seven Fleet Capital Management LP purchased a new position in shares of Celldex Therapeutics during the first quarter valued at approximately $929,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for diseases with significant unmet medical needs. The company's research programs address conditions in immunology, inflammation, oncology and other areas where targeted immune-system modulation may provide therapeutic benefits.

Celldex's lead investigational product is barzolvolimab, an antibody designed to block the KIT receptor and reduce mast cells. The therapy is being studied in immune-mediated diseases, including chronic spontaneous urticaria and prurigo nodularis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.